📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters. (2013)

First Author: Smith TA

Attributed to: Development of novel 18F-biotin conjugates for imaging pre-targeted antigens with positron emission tomography (PET) funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00280-012-2032-6

PubMed Identifier: 23178956

Publication URI: http://europepmc.org/abstract/MED/23178956

Type: Journal Article/Review

Volume: 71

Parent Publication: Cancer chemotherapy and pharmacology

Issue: 2

ISSN: 0344-5704